Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FNG is a topical probiotic skincare product developed by the Belgian company YUN for the management of foot and skin fungal infections, including athlete's foot. The formulation contains a proprietary blend of three live Lactobacillus strains: Lactiplantibacillus pentosus YUN-V1.0, Lactiplantibacillus plantarum YUN-V2.0, and Lacticaseibacillus rhamnosus YUN-S1.0. These beneficial bacteria are delivered via a patented micro-encapsulation technology that protects the live cultures and ensures their activation upon contact with the skin. The product works through "probiotherapy," a mechanism that restores the natural balance of the skin microbiome, thereby outcompeting pathogenic fungi and strengthening the skin's biological barrier. Although marketed as a cosmetic product, it was developed through extensive research at the University of Antwerp and has demonstrated efficacy in dermatological evaluations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FNG PROBIOTIC REPAIR Foot Spray.